**Efficacy of ranibizumab for the treatment of diabetic retinopathy**

A protocol for systematic review of randomized controlled trial

Yong-bo Ren, MM, Xing-jie Su, MM*, Yan-xiu Qi, MD, He-qun Luan, MB, Qi Sun, MM

**Abstract**

**Background:** Previous clinical trials have reported that ranibizumab can be used to treat diabetic retinopathy (DR) effectively. However, no study has been conducted to evaluate its efficacy for patients with DR systematically. Thus, this study will specifically and systematically assess the efficacy and safety of ranibizumab for DR.

**Methods:** Cochrane Library, EMBASE, PUBMED, Web of Science, Google Scholar, Cumulative Index to Nursing and Allied Health Literature, China National Knowledge Infrastructure, and Chinese Biomedical Literature Database will be searched from inceptions to the March 20, 2019 for studies related to the topic. This study will only consider publicly released randomized controlled trials for evaluating the effect and safety of ranibizumab for DR. No language restrictions will be imposed for all databases search. Methodological quality of each included trial will be assessed by Cochrane risk of bias tool. Statistical analysis will be performed by Stata 12.0 software.

**Results:** This study will provide recent summary evidence of ranibizumab for DR. Primary outcomes include percentages with retinopathy improvement, and cumulative probabilities for retinopathy worsening. Secondary outcome consist of visual function, best-corrected visual acuities, central subfield thickness, total macular volume, peripheral visual field loss, retinal neovascularization, and adverse events.

**Conclusion:** The findings of this study may provide theoretical basis for clinical practice refer and may benefit more patients with DR.

**Abbreviations:** CIs = confidence intervals, DM = diabetes mellitus, DR = diabetic retinopathy, RCTs = randomized controlled trials.

**Keywords:** diabetic retinopathy, efficacy, ranibizumab, safety, systematic review

---

**1. Introduction**

Diabetic retinopathy (DR) is one of the most common complications in patients with diabetes mellitus (DM), which account for about 40% of DM over 40 years of age. Previous study found that over 75% of patients with DM for more than 20 years will likely develop DR. It is also the leading cause of impaired vision and even blindness in patients with DM, and contributes 4.8% of 37 million cases of blindness worldwide.

Lots of clinical studies have reported that ranibizumab can be widely and effectively utilized to treat patients with DR with promising efficacy. However, no study has specifically addressed the efficacy and safety of ranibizumab for patients with DR. In this study, we specifically focused on assessing the efficacy and safety of ranibizumab for DR systematically.

---

**2. Methods**

**2.1. PROSPERO registration**

This study has been registered on PROSPERO with registration number PROSPERO CRD42019127058.

**2.2. Eligibility criteria**

**2.2.1. Types of trials.** This study will consider randomized controlled trials (RCTs) of ranibizumab as a way to improve DR without language restrictions. In addition to the RCTs, any other types of trials will all be excluded.

**2.2.2. Types of patients.** All the patients who meet the relevant diagnostic criteria for DR will be fully considered without any restrictions of race, age, gender, and case source.
2.2.3. Types of interventions. This study will utilize ranibizumab as an only intervention in the experimental group. However, in the control group, patients can receive any treatments.

2.2.4. Types of outcome measurements

2.2.4.1. Primary outcomes.
- Percentages with retinopathy improvement;
- Cumulative probabilities for retinopathy worsening.

2.2.4.2. Secondary outcomes.
- Visual function (as measured by National Eye Institute Visual Function Questionnaire-25 or other scales);
- Best-corrected visual acuities;
- Central subfield thickness;
- Total macular volume;
- Peripheral visual field loss;
- Retinal neovascularization;
- Any adverse events.

2.3. Search methods for the identification of eligible trials

Cochrane Library, EMBASE, PUBMED, Web of Science, Google Scholar, Cumulative Index to Nursing, and Allied Health Literature, China National Knowledge Infrastructure, and Chinese Biomedical Literature Database will be searched from inceptions to the March 20, 2019. The search language will not be limited. We will also search non-electronic papers manually, and reference lists of eligible trials, as well as relevant reviews. The search strategy with details is demonstrated in Table 1. In addition, similar search strategies will also be utilized to any other databases.

2.4. Study selection

Two investigators will scan the titles and abstracts independently to exclude any irrelevant studies. Then, full texts will be further assessed according to the predefined eligibility criteria. Any disputes regarding the study selection between 2 investigators will be resolved through the assistance of a third investigator. The whole process of study selection is abided to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [28] and PRISMA-Protocol guidelines. [29-30] Its results will be presented in a PRISMA flow chart with clearly reasons of exclusion and inclusion at each stage.

2.5. Data extraction and management

Two investigators will independently accomplish data extraction according to the previous designed data extraction form. A third investigator will be invited to solve any disputes between 2 investigators. It will collect and extract following information: including first author, time of publication, location, study setting, diagnostic criteria, eligibility criteria; age, gender, race, number of patients in each group; methods of randomization, concealment, and blinding; intervention details, drug, dosage, frequency, duration; all outcome indicators, and adverse events.

2.6. Missing data management

Whenever there is missing data or incomplete information, we will contact the primary authors to request those data by email or telephone. If those data is still not available, we will discuss its possible effects.

2.7. Risk of bias assessment

Risk of bias assessment will be completed by 2 investigators independently according to the standard criteria of Cochrane Handbook of Systematic Review of Interventions. It includes 7 items, and each item is further divided into 3 levels of high, unclear, and low risk of bias. Any disagreements regarding the risk of bias assessment between 2 investigators will be resolved by a third investigator through discussion.

2.8. Statistical analysis

Binary outcome data will be presented as risk ratio and 95% confidence intervals (CIs). Continuity outcome data will be represented as mean difference, or standardized mean difference and 95% CIs.

Heterogeneity among eligible RCTs will be identified by $I^2$ test. The value of $I^2 \leq 50\%$ indicates acceptable heterogeneity. Otherwise, the value of $I^2 > 50\%$ indicates significant heterogeneity. If there is acceptable heterogeneity, a fixed-effect model will be applied, and we will perform meta-analysis. On the other hand, if there is significant heterogeneity, a random-effect model
will be used, and group analysis will be carried out to identify any potential causes for the high heterogeneity.

2.9. Additional analysis

2.9.1. Subgroup analysis. Subgroup analysis will be carried out based on the different characteristics, interventions, controls, and outcomes to identify any potential factors that may result in the high heterogeneity.

2.9.2. Sensitivity analysis. Sensitivity analysis will be conducted to examine the stability for the analysis results by removing high risk of bias of eligible trials.

2.9.3. Reporting bias. Publication bias will be checked by Funnel plot and Egger regression test when sufficient RCTs are eligible, normally more than 10 studies.

3. Discussion

This systematic review is the first study to specifically assess the efficacy and safety of ranibizumab for patients with DR. It will comprehensively search a variety of databases without any language restrictions. Its results will supply a detailed summary of the up-to-date evidence relevant of ranibizumab for patients with DR. The evidence may be helpful to either the clinical practice and patients, or the health policy makers regarding the specific use of ranibizumab for patients with DR.

Author contributions

Conceptualization: Yong-bo Ren, Xing-jie Su, Yan-xiu Qi, He-qun Luan.

Data curation: Yong-bo Ren, Xing-jie Su, Qi Sun.

Formal analysis: Yong-bo Ren, Yan-xiu Qi, He-qun Luan, Qi Sun.

Funding acquisition: Yong-bo Ren.

Investigation: Xing-jie Su.

Methodology: Xing-jie Su, Yan-xiu Qi, He-qun Luan, Qi Sun.

Project administration: Xing-jie Su.

Resources: Yong-bo Ren, Yan-xiu Qi, He-qun Luan, Qi Sun.

Software: He-qun Luan, Qi Sun.

Supervision: Xing-jie Su, Yan-xiu Qi.

Validation: Yong-bo Ren, He-qun Luan, Qi Sun.

Visualization: Yong-bo Ren, Xing-jie Su, Qi Sun.

Writing - original draft: Yong-bo Ren, Xing-jie Su, Yan-xiu Qi, He-qun Luan, Qi Sun.

Writing - review & editing: Yong-bo Ren, Xing-jie Su, Yan-xiu Qi, Qi Sun.

References

[1] Lim SW, van Wijngaarden P, Harper CA, et al. Pathophysiology of diabetic retinopathy: the old and the new. Diabetes Metab J 2018;42:564–76.
[2] Lim SW, van Wijngaarden P, Harper CA, et al. Early worsening of diabetic retinopathy due to intensive glycemic control. Clin Exp Ophthalmol 2019;47:265–73.
[3] Sabanayagam C, Banu R, Chee ML, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol 2019;7:140–9.
[4] Adams AP. Is diabetic retinopathy an inflammatory disease? Brit J Ophthalmol 2002;86:363–5.
[5] Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: Wiley-Blackwell, 2008.
[6] Barcelo A, Aedo C, Rajpathak S, et al. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ 2003;81:19–27.
[7] Kowluw RA. Mitochondria damage in the pathogenesis of diabetic retinopathy and in the metabolic memory associated with its continued progression. Curr Med Chem 2013;20:3226–33.
[8] Resnikoff S, Pascolini D, Yoon J, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844–51.
[9] Bhattarai AR, Googe JMJr, Stockdale CR, et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-panretinal photocoagulation trials. Arch Ophthalmol 2009;127:1581–3.
[10] Messias A, Ramos Filho JA, Messias K, et al. Electoretinographic findings associated with panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab treatment for high-risk proliferative diabetic retinopathy. Doc Ophthalmol 2012;124:225–36.
[11] Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 2012;130:1145–52.
[12] Diabetic Retinopathy Clinical Research Network*Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 2013;131:283–93.
[13] Chae JB, Joe SG, Yang SJ, et al. Effect of combined cataract surgery and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy. Retina 2014;34:149–51.
[14] Bressler SB, Qin H, Melia M, et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol 2013;131:1033–40.
[15] Bhattarai AR, Torres K, Glassman AR, et al. Diabetic retinopathy clinical research network. Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy. JAMA Ophthalmol 2014;132:889–90.
[16] Ornek N, Ornek K, Erbaşçi IE. Concomitant and conjunctival sensitivity changes following intravitreal ranibizumab injection in diabetic retinopathy. J Ocul Pharmacol Ther 2015;31:37–42.
[17] Ferraz DA, Vasquez LM, Perti RC, et al. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy. Retina 2015;35:280–7.
[18] Pakdad-Vaezi K, Albani DA, Kirker AW, et al. A randomized study comparing the efficacy of bevacizumab and ranibizumab as pre-treatment for pars plana vitrectomy in proliferative diabetic retinopathy. Ophthal Surg Lasers Imaging Retina 2014;45:521–4.
[19] Ip MS, Domalpally A, Sun JK, et al. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology 2015;122:367–74.
[20] Gross JG, Glassman AR, Jampol LM, et al. Writing Committee for the Diabetic Retinopathy Clinical Research NetworkPanretinal photocoagulation versus intravitreal ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 2015;314:2137–46.
[21] Figueira J, Silva R, Henrauques J, et al. Ranibizumab for high-risk proliferative diabetic retinopathy: an exploratory randomized controlled trial. Ophthalmologica 2016;235:34–41.
[22] Ross EL, Hutton DW, Stein JD, et al. Cost-effectiveness of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema treatment: analysis from the diabetic retinopathy clinical research network comparative effectiveness trial. JAMA Ophthalmol 2016;134:888–96.
[23] Beaulieu WT, Bressler NM, Melia M, et al. Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: patient-centered outcomes from a randomized clinical trial. Am J Ophthalmol 2016;170:206–13.
[24] Bressler SB, Beaulieu WT, Glassman AR, et al. Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab. Ophthalmology 2017;124:431–9.
[25] Bressler SB, Liu D, Glassman AR, et al. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab. JAMA Ophthalmol 2017;135:558–68.
[26] Chitala P, Nehme J, El Rami H, et al. Efficacy of intravitreal ranibizumab injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy. Retina 2018;38:1127–33.
[27] Hutton DW, Stein JD, Bressler NM, et al. Cost-effectiveness of intravitreal ranibizumab compared with panretinal photocoagulation.
for proliferative diabetic retinopathy: secondary analysis from a diabetic retinopathy clinical research network randomized clinical trial. JAMA Ophthalmol 2017;135:576–84.

[28] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.

[29] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:3.

[30] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 elaboration and explanation. BMJ 2015;349:g7647.